CCS
ROIV icon

Concentric Capital Strategies’s Roivant Sciences ROIV Stock Holding History

Concentric Capital Strategies’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-150,275
Closed -$1.59M – 364
2024
Q2 		$1.59M Buy
+150,275
New +$1.65M 0.08% 221

Other funds holding ROIV

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Concentric Capital Strategies's ROIV Position: Q3 2024 in Review

Concentric Capital Strategies sold out of Roivant Sciences (ROIV) in Q3 2024, closing a stake of 150,275 shares — an estimated $1.59M sold.

Concentric Capital Strategies first reported a position in ROIV in Q2 2024 and held it in 1 quarter. The position peaked at $1.59M in Q2 2024. 293 funds tracked by Wall St. Rank hold ROIV as of Q3 2024.

  • Concentric Capital Strategies reported no remaining Roivant Sciences position as of Q3 2024 after selling out during the quarter.
  • Concentric Capital Strategies sold 150,275 Roivant Sciences shares in Q3 2024, an estimated $1.59M.
  • Concentric Capital Strategies first reported a position in Roivant Sciences in Q2 2024 and held it in 1 quarter.
  • Concentric Capital Strategies's Roivant Sciences position peaked at $1.59M in Q2 2024.
  • 293 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2024.

Based on Concentric Capital Strategies's 13F filing for Q3 2024, filed 14 Nov 2024.